Cuprina Holdings (Cayman) Limited Stock Price, News & Analysis

Cuprina Holdings (Nasdaq: CUPR) received a Nasdaq noncompliance notice dated November 26, 2025 for failing to meet the $1.00 minimum bid under Nasdaq Listing Rule 5550(a)(2).

Cuprina has an initial 180-calendar-day compliance period to regain the $1.00 closing bid for at least ten consecutive business days. If not regained, the company may be eligible for a second 180-day period by meeting market value and other initial listing standards (excluding the bid price) and providing written notice to cure, potentially by effecting a reverse stock split. Shares will continue to trade uninterrupted under the symbol CUPR while the process unfolds. Cuprina is evaluating options to regain compliance but stated there is no assurance it will do so.

Cuprina (Nasdaq: CUPR) signed a joint venture with Singapore-based Aiodine Laboratory to develop, test and commercialize Aiodine's novel iodine-based disinfectant for antiseptic wound care, disinfectants and daily home-use antiseptics, with additional applications under evaluation including personal care, oral hygiene and veterinary uses.

The JV assigns global sales, marketing and distribution to Cuprina and proprietary iodine technology to Aiodine. Clinical studies to pursue regulatory approvals are planned to commence in 2026. A peer-reviewed case series (March 26, 2025) reported wound improvement in three of four patients within two weeks without toxicity. Market references: wound care ≈ US$21B (2024) to US$36B (2032); antiseptics estimate ≈ US$48M (2027).

Cuprina (Nasdaq: CUPR) signed a Memorandum of Understanding on October 27, 2025 with Singapore Biowaste Solutions (SBS) to explore integrating Cuprina’s medical waste recycling technology into SBS’s Singapore facility.

The collaboration covers a feasibility study and pilot using Cuprina’s exclusive Southeast Asia license to a high-temperature autoclaving process that sterilizes and converts plastic medical waste into resins. Cuprina will provide technical expertise and training; SBS will provide operational data, facility access, and regulatory support. The partners will seek revenue-sharing models and regional expansion, and Cuprina expects regulatory approvals and operations could begin by end of 2026.

Cuprina (NASDAQ:CUPR) announced that management, including CEO David Quek, will present live and answer questions at the Skyline Signature Series™ on Wednesday, October 8, 2025 at 11:00 AM ET. The event is an interactive online presentation that allows investors to ask questions in real time. Interested individual and institutional investors, advisors, and analysts must pre-register to attend.

Registration is required via the event sign-up link and the presentation is scheduled as a live webcast format for investor engagement.

Cuprina Holdings (Nasdaq: CUPR) has secured exclusive licensing rights to Southeast Asia's first UNIDO/GEF-demonstrated medical waste recycling technology. The technology, licensed from Zhejiang Heliang Technology, uses advanced high-temperature steam treatment to sterilize and recycle medical waste into high-value resins, particularly focusing on plastic-based materials.

The license covers Singapore with expansion options to 10 additional Southeast Asian countries. The technology offers an environmentally friendly alternative to traditional incineration methods, supported by extensive regulatory approvals and ISO certifications (9001, 14001, 45001). Singapore's biohazardous medical waste increased from 4,400 tons in 2016 to 5,700 tons in 2020, growing approximately 5% annually.

The global medical waste management market is projected to grow from $34.06 billion in 2023 to $59.42 billion by 2030, with Asia-Pacific as the fastest-growing region.

Cuprina Holdings (NASDAQ:CUPR) has issued a statement addressing recent unusual trading volatility in its stock. The company emphasized that it remains fully operational and legally compliant, with no known operational reasons or material adverse events causing the stock fluctuations.

CEO David Quek confirmed that no initial shareholders or founding team members have sold their stock in the past week. The company is progressing with key milestones, including FDA clearance submission for medical maggot therapy, expansion into the GCC region, and exploring potential joint ventures in chronic wound management.

Cuprina, which completed its IPO earlier this year, maintains its commitment to transparency and execution of its business plan while focusing on advancing its biotherapeutic pipeline.

Cuprina Holdings (Nasdaq: CUPR) has made two significant announcements in the bio-therapeutics space. First, the company appointed Dr. Ronald A. Sherman, a pioneer in medical maggot therapy, as Medical and Scientific Director effective September 2025. Second, Cuprina secured a license for Dr. Sherman's 2004 FDA clearance to market Lucilia sericata Medical Maggots™ in the United States.

Dr. Sherman will lead clinical initiatives, develop training frameworks, and provide regulatory guidance. Cuprina is also pursuing FDA clearance for another maggot species, Lucilia cuprina, with potential approval expected within 90 business days. The U.S. market for maggot debridement therapy was valued at $13.9 million in 2024 and is projected to reach $24.8 million by 2030, growing at a 10.1% CAGR.

Cuprina Holdings (Nasdaq: CUPR) has provided updates on three one-year research studies with leading educational institutes focused on developing collagen peptide molecules from American bullfrog skin. The company has made significant progress in these collaborations:

With Republic Polytechnic, Cuprina identified methods to generate peptides for cosmeceutical applications. The collaboration with the Institute for Health Innovation and Technology at NUS is exploring bullfrog collagen peptides for 3D printable wound care dressings, including microneedling patches. The partnership with the Singapore Institute of Technology aims to produce superior powdered bullfrog collagen peptides.

Research has shown that bullfrog-derived collagen achieved 90% wound closure in 24 hours compared to 34% for bovine collagen. The global collagen peptides market is projected to grow from $699 million in 2023 to $922 million in 2028, at a CAGR of 5.7%.

Cuprina Holdings (NASDAQ: CUPR) has announced two significant developments in the MENA region. First, its 49%-owned associate, Cuprina MENA Co. Ltd, has completed setting up a laboratory in Saudi Arabia for manufacturing MEDIFLY maggot debridement therapy for chronic wound treatment. The company is now pursuing regulatory approvals, including Saudi FDA license and ISO 13485 certification. Second, Cuprina MENA has obtained exclusive rights from Biopharm UK Ltd to distribute medicinal leeches across GCC countries. These leeches are used to treat various medical conditions including venous congestion, post-surgical healing, osteoarthritis symptoms, and veterinary applications, particularly for treating polycythaemia vera.